NAFEEZA ALLI: Open Payments
NPI 1588264246 · HOLLYWOOD, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,023 in 230 payments from 19 companies in 2025. Trend: 2023 $4,113 · 2024 $3,950 · 2025 $5,023
Food & beverage: $5,023
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 23 | $629 |
| Axsome Therapeutics, Inc. | 17 | $527 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 26 | $468 |
| Teva Pharmaceuticals USA, Inc. | 26 | $415 |
| Otsuka America Pharmaceutical, Inc. | 17 | $405 |
| ABBVIE INC. | 22 | $379 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $352 |
| Vanda Pharmaceuticals Inc. | 11 | $324 |
| Bausch Health US, LLC | 14 | $313 |
| Indivior Inc. | 9 | $248 |
Products named: INGREZZA, Auvelity, CAPLYTA, REXULTI, VRAYLAR, TRINTELLIX, AUSTEDO XR, APLENZIN.
Industry payments across FL — which companies pay providers there.
